CN109161543A - 用于富集低频dna突变的dna探针及其应用 - Google Patents
用于富集低频dna突变的dna探针及其应用 Download PDFInfo
- Publication number
- CN109161543A CN109161543A CN201810845111.0A CN201810845111A CN109161543A CN 109161543 A CN109161543 A CN 109161543A CN 201810845111 A CN201810845111 A CN 201810845111A CN 109161543 A CN109161543 A CN 109161543A
- Authority
- CN
- China
- Prior art keywords
- dna
- low frequency
- mutation
- nucleotide
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009946 DNA mutation Effects 0.000 title claims abstract description 73
- 239000003298 DNA probe Substances 0.000 title claims abstract description 48
- 108020003215 DNA Probes Proteins 0.000 title claims abstract description 46
- 239000000523 sample Substances 0.000 claims abstract description 44
- 108020004414 DNA Proteins 0.000 claims abstract description 40
- 230000000295 complement effect Effects 0.000 claims abstract description 18
- 238000012986 modification Methods 0.000 claims abstract description 10
- 230000004048 modification Effects 0.000 claims abstract description 10
- 230000035772 mutation Effects 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 239000011324 bead Substances 0.000 claims description 26
- 239000002585 base Substances 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 239000003513 alkali Substances 0.000 claims description 21
- 238000012163 sequencing technique Methods 0.000 claims description 18
- 238000012408 PCR amplification Methods 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000012545 processing Methods 0.000 claims description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 108020004635 Complementary DNA Proteins 0.000 claims description 9
- 238000009396 hybridization Methods 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 230000000869 mutational effect Effects 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000004925 denaturation Methods 0.000 claims description 7
- 230000036425 denaturation Effects 0.000 claims description 7
- 238000013467 fragmentation Methods 0.000 claims description 7
- 238000006062 fragmentation reaction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 27
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 26
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 26
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 26
- 101150039808 Egfr gene Proteins 0.000 description 22
- 238000001514 detection method Methods 0.000 description 22
- 108700021358 erbB-1 Genes Proteins 0.000 description 22
- 239000000047 product Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 102200048928 rs121434568 Human genes 0.000 description 13
- 102200048955 rs121434569 Human genes 0.000 description 12
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000010355 oscillation Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000005352 clarification Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 231100000693 bioaccumulation Toxicity 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101150024963 Pu gene Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
1M NaOH | 125μL |
80mM EDTA | 100μL |
0.5g/l酚红 | 400μL |
水 | 375μL |
总体积 | 1000μL |
1M NaOH | 125μL |
80mM EDTA | 100μL |
0.5g/l酚红 | 400μL |
水 | 375μL |
总体积 | 1000μL |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810845111.0A CN109161543B (zh) | 2018-07-27 | 2018-07-27 | 用于富集低频dna突变的dna探针及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810845111.0A CN109161543B (zh) | 2018-07-27 | 2018-07-27 | 用于富集低频dna突变的dna探针及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109161543A true CN109161543A (zh) | 2019-01-08 |
CN109161543B CN109161543B (zh) | 2021-07-23 |
Family
ID=64898521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810845111.0A Active CN109161543B (zh) | 2018-07-27 | 2018-07-27 | 用于富集低频dna突变的dna探针及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109161543B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109628560A (zh) * | 2019-01-30 | 2019-04-16 | 杭州瑞普基因科技有限公司 | 用于富集低频dna突变的dna探针及其应用 |
CN109762901A (zh) * | 2019-01-30 | 2019-05-17 | 杭州瑞普基因科技有限公司 | 用于富集低频dna突变的dna探针应用于多种突变的同时检测 |
CN110396517A (zh) * | 2019-05-21 | 2019-11-01 | 珠海圣美生物诊断技术有限公司 | 一种用于扩增变异型靶基因片段的非淬灭型寡核苷酸探针及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101608240B (zh) * | 2009-04-13 | 2011-06-29 | 郑立谋 | 用于检测人类egfr基因突变的引物、探针及其使用方法 |
CN105324492A (zh) * | 2013-03-26 | 2016-02-10 | 健能泰格技术公司 | 用于dna和rna检测的双探针:反探针组合物 |
CN104762408B (zh) * | 2015-04-29 | 2017-06-20 | 苏州工业园区为真生物医药科技有限公司 | 检测egfr基因突变的试剂盒及其检测方法 |
CN108048531B (zh) * | 2017-11-16 | 2021-06-18 | 苏州吉玛基因股份有限公司 | 一种高灵敏度检测稀有突变的超阻滞荧光定量pcr方法 |
-
2018
- 2018-07-27 CN CN201810845111.0A patent/CN109161543B/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109628560A (zh) * | 2019-01-30 | 2019-04-16 | 杭州瑞普基因科技有限公司 | 用于富集低频dna突变的dna探针及其应用 |
CN109762901A (zh) * | 2019-01-30 | 2019-05-17 | 杭州瑞普基因科技有限公司 | 用于富集低频dna突变的dna探针应用于多种突变的同时检测 |
CN110396517A (zh) * | 2019-05-21 | 2019-11-01 | 珠海圣美生物诊断技术有限公司 | 一种用于扩增变异型靶基因片段的非淬灭型寡核苷酸探针及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109161543B (zh) | 2021-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108034658B (zh) | 一种检测人葡萄膜黑色素瘤细胞的核酸适体 | |
CN110100013A (zh) | 用于肿瘤检测的方法和系统 | |
CN107663533A (zh) | 一种肺癌EGFR L858R和19Del的ddPCR检测方法及应用 | |
CN109161543A (zh) | 用于富集低频dna突变的dna探针及其应用 | |
CN105219867B (zh) | 用于胃癌诊断的miRNA生物标志物及检测试剂盒 | |
CN104593372A (zh) | 一种检测胰腺导管癌的核酸适配体、试剂盒及方法 | |
CN104032001B (zh) | 用于胆囊癌预后评估的erbb信号通路突变靶向测序方法 | |
CN110004147B (zh) | 一种在人血浆中筛选的上皮细胞粘附分子EpCAM的核酸适体及其制备方法和应用 | |
CN112680452A (zh) | 一种特异性结合肺癌血清的寡核苷酸适配体及应用 | |
CN110295172B (zh) | 一种快速筛选的肾癌核酸适体及其制剂在制备检测中的应用 | |
CN106399304A (zh) | 一种与乳腺癌相关的snp标记 | |
CN108531586A (zh) | 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用 | |
CN106032534B (zh) | 一种与人非小细胞肺癌细胞特异结合的核糖核酸适配体及其筛选方法 | |
CN108265055B (zh) | 特异性结合人乳腺癌细胞mcf-7的dna核酸适配体及其应用 | |
CN105063052B (zh) | 急性髓系白血病miRNA标记物 | |
CN105219841B (zh) | 一种肺癌差异性表达microRNA的检测试剂盒及其应用 | |
CN106282194B (zh) | 人乳腺癌细胞株特异性核酸适配体及其在制备检测、诊断和治疗人乳腺癌制剂中的应用 | |
CN110317878A (zh) | 一种用于膀胱癌诊治监测的长链非编码rna及其应用 | |
AU703262B2 (en) | Immuno-magnetic cell separation used in identification of genes associated with site-preferenced cancer methastasis formation | |
CN112501295B (zh) | miRNA组合、含其的试剂盒及在肺癌诊断中的应用 | |
CN104962612B (zh) | BRCA1基因g.41256139delT移码突变及其在制备乳腺癌辅助诊断试剂盒中的应用 | |
CN109762901A (zh) | 用于富集低频dna突变的dna探针应用于多种突变的同时检测 | |
CN105169393B (zh) | miRNA-548a-3p抗急性髓系白血病中的应用 | |
CN110066876A (zh) | 一种用于癌症诊断的分子标志物 | |
CN109628560A (zh) | 用于富集低频dna突变的dna探针及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: DNA probe for enriching low frequency DNA mutation and its application Effective date of registration: 20211206 Granted publication date: 20210723 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2021980014102 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220322 Granted publication date: 20210723 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2021980014102 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: DNA probe for enriching low frequency DNA mutation and its application Effective date of registration: 20220322 Granted publication date: 20210723 Pledgee: Shanghai Guotai Junan Securities Asset Management Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2022990000158 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221220 Granted publication date: 20210723 Pledgee: Shanghai Guotai Junan Securities Asset Management Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2022990000158 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20190108 Assignee: Hangzhou Jintou Finance Leasing Co.,Ltd. Assignor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Contract record no.: X2022980028715 Denomination of invention: DNA probe for enrichment of low-frequency DNA mutation and its application Granted publication date: 20210723 License type: Exclusive License Record date: 20230112 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: DNA probe for enrichment of low-frequency DNA mutation and its application Effective date of registration: 20230115 Granted publication date: 20210723 Pledgee: Hangzhou Jintou Finance Leasing Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2023980031387 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Hangzhou Jintou Finance Leasing Co.,Ltd. Assignor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Contract record no.: X2022980028715 Date of cancellation: 20240327 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210723 Pledgee: Hangzhou Jintou Finance Leasing Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2023980031387 |